Remote Respiratory Monitoring to Enhance Disease Surveillance
The RESP® Biosensor
FDA 510(k) Class II | CE Mark | HIPAA Compliant
Technology Overview
The RESP® Biosensor offers clinicians and healthcare teams a new approach to managing at-risk patients with chronic respiratory diseases such as COPD and asthma.
- Continuous and passive lung sound monitoring to extend the range of stethoscope auscultation and in-person assessments¹
- Patient-friendly form factor that respects patient comfort and lifestyle.
- Physiological data including heart rate*, heart rate variability*, and respiratory rate*
*Measurement not yet FDA cleared
1. Equivalent performance to 3M Littman 3200 Electronic Stethoscope (source)
OVERVIEW VIDEO
“With this information we can predict if the patient is doing better or worse and intervene ahead of time to prevent the patient from having major complications”
– Sadia Benzaquen, MD, Chair of Pulmonary Critical Care, Einstein Medical Center
Seamless, Remote Respiratory Monitoring
KEY FEATURES
- Passive and continuous
- Notifications and alerts
- HIPAA compliant
- Reimbursable under RTM & RPM codes
- 24+ hour battery life & rechargeable
- EHR/telehealth integration
- Water resistant
- Flexible reporting options including automated* and human analysis
*Machine learning algorithms not FDA cleared
Lung sound recordings captured by the biosensor are depicted visually as spectrograms
Cough
Wheeze
Crackles
Interested in a Research Collaboration?
We’re seeking clinical and academic collaborators to explore how wearable respiratory technologies can improve patient outcomes. Partners may be eligible for in-kind support.
RESP® Biosensor Care Settings
Home Monitoring
- Remote monitoring of at-risk COPD & Asthma patients
- Interstitial lung diseases
- Heart failure
- Pulmonary Rehabilitation
Acute Care
- In-patient status monitoring
- Chronic, complex care management
- Hospital at Home
- Tele-ICUs
Post-Acute Care
- Post-discharge hospital to home
- Post-surgical recovery and rehabilitation
- Skilled-nursing and long-term care facilities
Potential to Detect Exacerbations Earlier¹
1. Case Study of an adult AE-COPD patient using the RESP Biosensor. Einstein Hospital, Philadelphia. https://journal.chestnet.org/article/S0012-3692(23)04216-2/fulltext
Remote Monitoring Practice Application
Patient is prescribed RESP® Biosensor for two weeks
On day 5, clinician receives alert of increased coughing and wheezing
Clinician checks in with patient virtually and adjusts treatment plan to avoid a readmission
Publications
View our clinical validation, whitepapers and case studies
Increasing Abnormal Lung Sounds After Discharge Predicts COPD Readmission
Poster Presentation, CHEST, 2023
Remote Auscultation At Home After Asthma Exacerbation: A Case from Discharge to Readmission
Poster Presentation, American Thoracic Society, 2020
Poster Presentation, American Thoracic Society, 2022
Talk to our Team
Reach out to explore using the RESP Biosensor in your practice